Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody-Drug Conjugate Plus Stereotactic Body Radiotherapy in Recurrent or Metastatic Salivary Gland Carcinoma
NCT07579598Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of becotatug vedotin, sacituzumab tirumotecan in salivary gland carcinoma (SGC), sponsored by Shanghai Ninth People's Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinsacituzumab tirumotecan
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT07579598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579598.